Actavis CEO: Teva-Mylan Deal to Create ‘Bad Blood’, Destroy Value
As Israeli pharmaceutical giant Teva pushes ahead with a $40-billion dollar hostile bid for US generic drugmaker Mylan, Brent Saunders, CEO of rival drug manufacturer Actavis, has raised concerns More...
Allergan CEO Says Fighting Off Activist Bill Ackman Was Full Time Job
One thing Allergan CEO David Pyott enjoyed doing was running his company. When activist investor Bill Ackman of Pershing Square decided to have Valeant Pharmaceuticals try to swallow up the Botox maker in a More...
Bill Ackman Not Likely to Plunk Down Cash Hoard Anytime Soon
The comparatively low level of cash assets currently held by hedge fund mogul Bill Ackman probably means that he won’t be making any activist investments for the next few months. Ackman’s $18.3 billion Pershing More...
Alpha Wolf Bill Ackman Is Top Dog on Wall Street
Bill Ackman might be controversial, but he had the top performing hedge fund of 2014, as reported by Bloomberg. While he was ridiculed the previous year for his pressure to put Ron Johnson of AppleStores as More...
Is Bill Ackman Guilty of Insider Trading?
Bill Ackman has cleaned up this year to the tune of $1 billion. He has also profited from Actavis’ announced merger with Botox maker Allergan, although for many months, he was pushing the company to accept More...
Ackman’s Pershing Square sees big payoff from Allergan deal
– Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm’s biggest bet of 2014. One week after Allergan agreed More...
Actavis Saves Allergan from Valeant Hostile Takeover with $66 Billion Deal, But Will Slash R&D
The seven-month battle over American Botox haven pharmaceutical company Allergan is over, after it accepted a friendly takeover bid from Irish integrated specialty pharmaceutical Actavis. The Actavis offer More...
Bill Ackman Finally Throws in the Towel with Allergan Shareholders’ Meeting
After an intense and acrimonious months long battle for a hostile takeover of Allergan, Bill Ackman, who owns a 9.7% stake in the company, finally gave up his battle to convene a special shareholders’ More...
Jim Cramer: Is Zoetis Fending Off Ackman?
On CNBC’s Mad Dash segment, Jim Cramer discussed “one of my favorite stocks, ” Zoetis, an animal health drug company spun off by Pfizer. Cramer says he likes the stock, because animal More...
Ackman supports Allergan’s $66 billion sale to Actavis
– Activist investor William “Bill” Ackman said on Tuesday he supports the $66 billion deal in which Actavis PLC will buy Allergan Inc and will withdraw his request for an Allergan special shareholder More...